Kura Oncology reported $5.8 million in net sales of KOMZIFTI (ziftomenib) in its first full quarter of commercialization, showing strong early adoption with 85 new patient starts and broad payer coverage over 93%. The company is advancing multiple clinical trials for ziftomenib in acute myeloid leukemia (AML), including ongoing Phase 3 frontline and combination studies, with several data readouts expected in 2026. Kura also presented promising data for its solid tumor drug darlifarnib and expects to sustain growth through commercial execution and clinical milestones. The company holds $580.8 million in cash and anticipates collaboration payments to fund development through pivotal trial results expected in 2028.
In 2026, bitcoin price predictions vary widely, with forecasts ranging from a low of $40,000 to a high of $1.5 million. Key figures like Arthur Hayes expect bitcoin to reach $125,000 by year-end, while Michael Saylor projects $1 million by the decade...
Top futures traders are increasing long positions in major altcoins Dogecoin and Ethereum, signaling a rise in short-term risk appetite. Dogecoin's long exposure rose notably in both dollar-margined and coin-margined markets, indicating strong direct...
DeXe (DEXE) surged 22% to $17.65 after breaking above the $16 resistance level that had capped its price since April 2025. Trading volume nearly doubled to $42.5 million, signaling strong market support for the breakout. Technical indicators like the...
Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, includi...
Chun Wang, co-founder of F2Pool, one of the largest Bitcoin mining pools, has been named commander of SpaceX's inaugural private Mars flyby mission. Wang funded his seat through wealth accumulated by mining over 1.3 million Bitcoins and launching a s...
